Article Text
Statistics from Altmetric.com
- Allocation of healthcare resources
- government/criminal justice
- embryos and fetuses
- philosophical ethics
- genetic screening/testing
Is NICE ageist?
In the UK, new health technologies are assessed by the National Institute for Clinical Excellence (NICE). NICE determines the cost incurred for each additional quality-adjusted life-year (QALY) that the new technology provides over and above the currently standard treatment. Though there is considerable flexibility in the process, technologies which offer a cost-per-QALY of £20 000-£30 000 or less would normally be recommended for use. The thought is that, given a fixed total health budget, use of technologies with a higher cost-per-QALY will generally decrease aggregate health by displacing more cost-effective interventions.
One criticism levelled at NICE maintains that its methodology is ageist. Since younger people typically have a longer life expectancy than older people, a life-saving treatment will tend to produce more QALYs in a younger person. So too will a quality-of-life-improving intervention, since it will improve quality of life over a longer period. The NICE approach might be said to systematically favour younger people.
In this issue, Stevens and collaborators (see page 258) respond …
Linked Articles
Other content recommended for you
- On the random distribution of scarce doses of vaccine in response to the threat of an influenza pandemic: a response to Wardrope
- Justice and the NICE approach
- Ethical allocation of future COVID-19 vaccines
- Vaccine ethics: an ethical framework for global distribution of COVID-19 vaccines
- Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries
- Scarce vaccine supplies in an influenza pandemic should not be distributed randomly: reply to McLachlan
- Should vaccination status be a consideration during secondary triage?
- NICE is dead; long live NICE
- What is fair? Ethical analysis of triage criteria and disability rights during the COVID-19 pandemic and the German legislation
- National Institute for Health and Clinical Excellence appraisal and ageism